Digital Telemetry Implant Saves Researchers Time and Money by Collecting More Data From One Implant
ST. PAUL, Minn. and HOLLISTON, Mass., May 15, 2019 (GLOBE NEWSWIRE) -- Data Sciences International (DSI), a subsidiary of Harvard Bioscience, Inc. (Nasdaq: HBIO) and the global leader in wireless physiologic monitoring, will showcase its new PhysioTel™ Digital L11R cardiopulmonary implant at the American Thoracic Society Meeting in Dallas on May 19-21.
Launched in April 2019, this is the final upgrade from the legacy large animal platform to PhysioTel Digital. The PhysioTel Digital L11R replaces the D70-PCTR, the original cardiopulmonary implant. The L11R maintains the versatility of its predecessor by monitoring pressure, biopotential, temperature, respiratory volume, respiratory rate and activity while incorporating enhancements from the PhysioTel Digital platform. These enhancements include:
- Social housing compatibility with a wide range of enclosures
- Automated configuration eliminates human errors and provides a fast study start-up
- Encoded animal ID ensures traceability and GLP compliance
- Remote programming for convenient, safe and easy device battery management
The L11R allows safety pharmacology clients to combine previously separate cardiovascular and respiratory studies. Eliminating the additional study saves clients time and money while reducing the number of animals required. In addition, biodefense researchers may use the L11R for both dosimetry and improved disease state monitoring. Combining respiratory and cardiovascular endpoints results in a more accurate assessment of dosing and disease course. This enables better translation to clinical benefits in humans, thus faster FDA approval through the Animal Rule.
“The trend among researchers is to collect as much information in as few studies as possible,” said
, President and CEO of Harvard Bioscience. “Our customers have asked for an implant capable of simultaneously collecting cardiovascular and respiratory endpoints for the PhysioTel Digital platform. We are confident this implant will reinforce DSI’s position as the industry leader.”
About Data Sciences International
Data Sciences International (DSI) provides a complete preclinical platform to assess physiological data for research ranging from basic, to drug discovery, and drug development. DSI is the leading provider of telemetry systems, pulmonary solutions, associated software platforms, and services. DSI is a subsidiary of Harvard Bioscience (Nasdaq: HBIO) a global developer, manufacturer, and marketer of a broad range of specialized products for life science research.
About Harvard Bioscience
Harvard Bioscience is a global developer, manufacturer and marketer of a broad range of solutions to advance life science. Our products are sold to thousands of researchers in over 100 countries through our global sales organization, websites, catalogs, and through distributors including Thermo Fisher Scientific Inc., VWR, GE Healthcare, and other specialized distributors. We have sales and manufacturing operations in the United States, the United Kingdom, Germany, Sweden, Spain, France, Canada and China. For more information, please visit our website at www.harvardbioscience.com.